ENOV Stock Overview
Operates as a medical technology company focus on developing clinically differentiated solutions worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Enovis Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$43.95 |
| 52 Week High | US$65.03 |
| 52 Week Low | US$38.27 |
| Beta | 2.02 |
| 1 Month Change | -7.94% |
| 3 Month Change | 0.73% |
| 1 Year Change | -22.24% |
| 3 Year Change | -68.24% |
| 5 Year Change | -60.42% |
| Change since IPO | -30.24% |
Recent News & Updates
Recent updates
Enovis Corporation's (NYSE:ENOV) Shares Not Telling The Full Story
Dec 13
Here's Why Enovis (NYSE:ENOV) Can Afford Some Debt
Sep 24It's A Story Of Risk Vs Reward With Enovis Corporation (NYSE:ENOV)
Aug 20Enovis Languishing Despite Respectable Performance
Jul 15Here's Why Enovis (NYSE:ENOV) Can Afford Some Debt
Jun 07Enovis: Solid Growth, But Unstable Financial Footing
May 05Enovis Corporation (NYSE:ENOV) Might Not Be As Mispriced As It Looks
Apr 22Estimating The Intrinsic Value Of Enovis Corporation (NYSE:ENOV)
Feb 12Is Enovis (NYSE:ENOV) Using Too Much Debt?
Jan 14Investors Holding Back On Enovis Corporation (NYSE:ENOV)
Dec 18Calculating The Fair Value Of Enovis Corporation (NYSE:ENOV)
Nov 05Enovis Making Good Choices, But Not Seeing The Rewards
Sep 27Is Enovis (NYSE:ENOV) A Risky Investment?
Sep 22Estimating The Intrinsic Value Of Enovis Corporation (NYSE:ENOV)
Aug 03Enovis Corporation: Things Are Looking Good As Guidance Is Raised
Jul 18We Think Enovis (NYSE:ENOV) Has A Fair Chunk Of Debt
Jun 20Enovis Corporation Q4 2022 Earnings Preview
Feb 22Is Enovis (NYSE:ENOV) A Risky Investment?
Feb 22Is Enovis Corporation (NYSE:ENOV) Worth US$60.5 Based On Its Intrinsic Value?
Jan 25Enovis Corporation reports Q3 earnings beat; updates FY22 guidance
Nov 02Is Enovis (NYSE:ENOV) A Risky Investment?
Oct 19Is Enovis Corporation (NYSE:ENOV) Trading At A 27% Discount?
Sep 14Enovis launches augmented reality system ARVIS for use in hip, knee surgery
Jul 19Here's Why Enovis (NYSE:ENOV) Can Manage Its Debt Responsibly
Jul 05Enovis announces CFO transition
Jun 30Enovis: Medtech Leftover Of Colfax With Some To Prove
May 23As The Colfax Chapter Ends, Both ESAB And Enovis Have Something To Prove
Apr 05Shareholder Returns
| ENOV | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 3.4% | 2.3% | 2.8% |
| 1Y | -22.2% | 10.1% | 24.5% |
Return vs Industry: ENOV underperformed the US Medical Equipment industry which returned 10.5% over the past year.
Return vs Market: ENOV underperformed the US Market which returned 24.8% over the past year.
Price Volatility
| ENOV volatility | |
|---|---|
| ENOV Average Weekly Movement | 4.8% |
| Medical Equipment Industry Average Movement | 7.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.1% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ENOV has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ENOV's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 6,550 | Matt Trerotola | www.enovis.com |
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.
Enovis Corporation Fundamentals Summary
| ENOV fundamental statistics | |
|---|---|
| Market cap | US$2.46b |
| Earnings (TTM) | -US$121.38m |
| Revenue (TTM) | US$2.00b |
1.2x
P/S Ratio-20.2x
P/E RatioIs ENOV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ENOV income statement (TTM) | |
|---|---|
| Revenue | US$2.00b |
| Cost of Revenue | US$821.68m |
| Gross Profit | US$1.18b |
| Other Expenses | US$1.30b |
| Earnings | -US$121.38m |
Last Reported Earnings
Sep 27, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.17 |
| Gross Margin | 58.95% |
| Net Profit Margin | -6.06% |
| Debt/Equity Ratio | 40.4% |
How did ENOV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 02:54 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/27 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Enovis Corporation is covered by 34 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jeffrey Johnson | Baird |
| null null | Baird |
| Robert Cornell | Barclays |